R406 reduces lipopolysaccharide-induced neutrophil activation
Seth Warner, Heather Teague, Marcos J. Ramos-Benítez, Sumith R. Panicker, Kiana Allen, Salina Gairhe, Tom Moyer, Bindu Parachalil Gopalan, Iyadh Douagi, Arun S. Shet, Yogendra Kanthi, Anthony F. Suffredini, Daniel S. Chertow, Jeffrey R. Strich
Abstract
Modulating SYK has been demonstrated to have impacts on pathogenic neutrophil responses in COVID-19. During sepsis, neutrophils are vital in early bacterial clearance but also contribute to the dysregulated immune response and organ injury when hyperactivated. Here, we evaluated the impact of R406, the active metabolite of fostamatinib, on neutrophils stimulated by LPS. We demonstrate that R406 was able to effectively inhibit NETosis, degranulation, ROS generation, neutrophil adhesion, and the formation of CD16low neutrophils that have been linked to detrimental outcomes in severe sepsis. Further, the neutrophils remain metabolically active, capable of releasing cytokines, perform phagocytosis, and migrate in response to IL-8. Taken together, this data provides evidence of the potential efficacy of utilizing fostamatinib in bacterial sepsis.